Literature DB >> 18258137

Increasing resistance in commensal Escherichia coli, Bolivia and Peru.

Alessandro Bartoloni, Lucia Pallecchi, Costanza Fiorelli, Tiziana Di Maggio, Connie Fernandez, Ana Liz Villagran, Antonia Mantella, Filippo Bartalesi, Marianne Strohmeyer, Angela Bechini, Herlan Gamboa, Hugo Rodriguez, Charlotte Kristiansson, Göran Kronvall, Eduardo Gotuzzo, Franco Paradisi, Gian Maria Rossolini.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18258137      PMCID: PMC2600201          DOI: 10.3201/eid1402.070138

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


× No keyword cloud information.
To the Editor: The global increase of antimicrobial-drug resistance, including resistance to the new and most potent antimicrobial agents, is a major public health concern. In low-resource countries, where bacterial infections are still among the major causes of death, especially for children, it is of particular concern (). ANTRES (Towards Controlling Antimicrobial Use and Resistance in Low-income Countries—An Intervention Study in Latin America) is a research project on antimicrobial-drug use and resistance in low-resource countries of Latin America (see www.unifi.it/infdis/antres/default.htm). In 2002, the baseline ANTRES study showed a high rate of fecal carriage of Escherichia coli with acquired resistance to several antimicrobial drugs, especially older drugs (e.g., ampicillin, trimethoprim-sulfamethoxazole, tetracycline, streptomycin, and chloramphenicol), in preschool children from 4 urban settings in Bolivia and Peru (). We report the results of a second cross-sectional study, conducted in 2005, that evaluated the evolution of antimicrobial-drug resistance in the studied areas. We studied healthy children 6–72 months of age from each of 4 urban areas: 2 in Bolivia (Camiri, Santa Cruz Department; Villa Montes, Tarija Department) and 2 in Peru (Yurimaguas, Loreto Department; Moyobamba, San Martin Department). The study design, sampling and inclusion criteria, methods, and ethical issues were the same as those of the baseline study (). The study was carried out over 4 months (September–December 2005), the same seasonal period as in the previous study. No significant differences in sex ratios were found among children enrolled from the different areas, whereas minor differences were found for age. No statistical differences were found between the 2002 baseline study and the 2005 study results in terms of numbers of children (3,193 vs. 3,174) and sex ratios (0.94 vs. 0.95) (Table). Statistical analyses were performed by using Stata 9.0 (Stata Corp., College Station, TX, USA). Logistic regression models were used to compare the antimicrobial-drug resistance rates in 2002 and 2005, considering the combined influences of age, sex, city, and country.
Table

Antimicrobial drug–resistance rates of Escherichia coli as part of 
commensal flora in children, Bolivia and Peru, 2002 and 2005*
*Expanded Table available online at www.cdc.gov/EID/content/14/2/338-T.htm.

Drug†20022005p value‡
AMP9596<0.05
CRO0.11.7<0.001
TET9393NS
SXT9494NS
CHL7069NS
STR8292<0.001
KAN2829<0.05
GEN2127<0.001
AMK0.40.1NA
NAL3557<0.001
CIP1833<0.001

Prevalence expressed as percentages. In 2002, n = 3,174, mean age 34.8 mo; in 2005, n = 3,193, mean age 33.7 mo (mean age p<0.05). 
†AMP, ampicillin; CRO, ceftriaxone; TET, tetracycline; SXT, trimethoprim-sulfamethoxazole; CHL, chloramphenicol; STR, streptomycin; KAN, kanamycin; GEN, gentamicin; AMK, amikacin; NAL, nalidixic acid; CIP, ciprofloxacin. 
‡Wald test applied to establish the statistical significance of parameters obtained from logistic regression analysis; NS, not significant; NA, not applicable (due to lack of variability of data).

Prevalence expressed as percentages. In 2002, n = 3,174, mean age 34.8 mo; in 2005, n = 3,193, mean age 33.7 mo (mean age p<0.05). 
†AMP, ampicillin; CRO, ceftriaxone; TET, tetracycline; SXT, trimethoprim-sulfamethoxazole; CHL, chloramphenicol; STR, streptomycin; KAN, kanamycin; GEN, gentamicin; AMK, amikacin; NAL, nalidixic acid; CIP, ciprofloxacin. 
‡Wald test applied to establish the statistical significance of parameters obtained from logistic regression analysis; NS, not significant; NA, not applicable (due to lack of variability of data). Data from the 2005 survey confirmed high resistance rates for ampicillin, trimethoprim-sulfamethoxazole, tetracycline, streptomycin, and chloramphenicol. The differences in resistance rates observed between 2002 and 2005 for these drugs, although sometimes statistically significant, are probably of limited epidemiologic relevance due to the high rates of antimicrobial-drug resistance found in the E. coli population in both surveys. The most relevant finding of the 2005 survey was the remarkable increase since 2002 in the resistance rates to fluoroquinolones and expanded-spectrum cephalosporins (Table). Molecular analysis showed that the dramatic increase in rates of resistance to expanded spectrum cephalosporins was mostly the result of dissemination of CTX-M-type extended-spectrum β-lactamase determinants (). Concerning the association between sex and resistance rates, the higher resistance rates observed for some agents and in some settings for boys in the baseline study were not confirmed, except in 1 case (kanamycin in Camiri, p = 0.04) (). Analysis by age (not performed for amikacin due to low numbers of resistant isolates) confirmed the occurrence of higher resistance rates for the youngest age group and an overall decreasing trend by age for all agents, except ciprofloxacin and gentamicin. For these 2 agents, resistance rates increased, although not significantly (p = 0.95 and p = 0.55, respectively) (). Although we did not specifically address factors potentially involved in this phenomenon, we will address them in future investigations. Increasing resistance to fluoroquinolones and expanded-spectrum cephalosporins among E. coli clinical isolates has been observed in several parts of the world and complicates the management of infections (,). Recently, intestinal colonization with fluoroquinolone-resistant or extended-spectrum β-lactamase–producing E. coli of nonhospitalized persons has been described as an emerging phenomenon (–). Although the exact clinical implications of this phenomenon are not clearly established, colonization by these resistant strains is a public health threat at the community and hospital levels (,). The reasons for the increased prevalence of fecal carriage of these resistant E. coli strains by children from the studied areas are not clear. Data collected about household use of antimicrobial drugs excluded previous use of fluoroquinolones and expanded-spectrum cephalosporins (C. Kristiansson et al., unpub. data). The increased prevalence of resistant E. coli strains in preschool children most likely reflects increased exposure within a contaminated household setting, in the food chain, or both (,,). Our findings support the need to continue monitoring the evolution of resistance in commensal E. coli, to evaluate the effects of these important reservoirs of resistance genes distributed in the community, to investigate the epidemiologic relationship with clinical isolates, and to define the role of the food supply. Investigation into whether carriage of resistant strains in adults correlates with data on antimicrobial-drug use in hospitals and in the community would also be of interest.
  9 in total

1.  Fluoroquinolone-resistant Escherichia coli: food for thought.

Authors:  Peter Collignon; Frederick J Angulo
Journal:  J Infect Dis       Date:  2006-05-31       Impact factor: 5.226

2.  A change in the epidemiology of infections due to extended-spectrum beta-lactamase-producing organisms.

Authors:  Jesus Rodriguez-Baño; David L Paterson
Journal:  Clin Infect Dis       Date:  2006-02-27       Impact factor: 9.079

Review 3.  Resistance in gram-negative bacteria: enterobacteriaceae.

Authors:  David L Paterson
Journal:  Am J Med       Date:  2006-06       Impact factor: 4.965

Review 4.  The worldwide emergence of plasmid-mediated quinolone resistance.

Authors:  Ari Robicsek; George A Jacoby; David C Hooper
Journal:  Lancet Infect Dis       Date:  2006-10       Impact factor: 25.071

5.  Phenotypic and genotypic characterization of fecal Escherichia coli isolates with decreased susceptibility to fluoroquinolones: results from a large hospital-based surveillance initiative.

Authors:  Ebbing Lautenbach; Neil O Fishman; Joshua P Metlay; Xiangqun Mao; Warren B Bilker; Pam Tolomeo; Irving Nachamkin
Journal:  J Infect Dis       Date:  2006-05-31       Impact factor: 5.226

6.  Similarity between human and chicken Escherichia coli isolates in relation to ciprofloxacin resistance status.

Authors:  James R Johnson; Michael A Kuskowski; Megan Menard; Abby Gajewski; Mariona Xercavins; Javier Garau
Journal:  J Infect Dis       Date:  2006-05-31       Impact factor: 5.226

7.  Influx of extended-spectrum beta-lactamase-producing enterobacteriaceae into the hospital.

Authors:  R Ben-Ami; M J Schwaber; S Navon-Venezia; D Schwartz; M Giladi; I Chmelnitsky; A Leavitt; Y Carmeli
Journal:  Clin Infect Dis       Date:  2006-02-27       Impact factor: 9.079

8.  Rapid dissemination and diversity of CTX-M extended-spectrum beta-lactamase genes in commensal Escherichia coli isolates from healthy children from low-resource settings in Latin America.

Authors:  Lucia Pallecchi; Alessandro Bartoloni; Costanza Fiorelli; Antonia Mantella; Tiziana Di Maggio; Herlan Gamboa; Eduardo Gotuzzo; Göran Kronvall; Franco Paradisi; Gian Maria Rossolini
Journal:  Antimicrob Agents Chemother       Date:  2007-06-04       Impact factor: 5.191

9.  Multidrug-resistant commensal Escherichia coli in children, Peru and Bolivia.

Authors:  Alessandro Bartoloni; Lucia Pallecchi; Marta Benedetti; Connie Fernandez; Yolanda Vallejos; Elisa Guzman; Ana Liz Villagran; Antonia Mantella; Chiara Lucchetti; Filippo Bartalesi; Marianne Strohmeyer; Angela Bechini; Herlan Gamboa; Hugo Rodríguez; Torkel Falkenberg; Göran Kronvall; Eduardo Gotuzzo; Franco Paradisi; Gian Maria Rossolini
Journal:  Emerg Infect Dis       Date:  2006-06       Impact factor: 6.883

  9 in total
  11 in total

1.  Prevalence and characterisation of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli isolates in healthy volunteers in Tunisia.

Authors:  R Ben Sallem; K Ben Slama; V Estepa; A Jouini; H Gharsa; N Klibi; Y Sáenz; F Ruiz-Larrea; A Boudabous; C Torres
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-11-08       Impact factor: 3.267

2.  High prevalence of qnr genes in commensal enterobacteria from healthy children in Peru and Bolivia.

Authors:  Lucia Pallecchi; Eleonora Riccobono; Antonia Mantella; Filippo Bartalesi; Samanta Sennati; Herlan Gamboa; Eduardo Gotuzzo; Alessandro Bartoloni; Gian Maria Rossolini
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

3.  Increased carriage of macrolide-resistant fecal E. coli following mass distribution of azithromycin for trachoma control.

Authors:  Jessica C Seidman; Christian L Coles; Ellen K Silbergeld; Joshua Levens; Harran Mkocha; Lashaunda B Johnson; Beatriz Muñoz; Sheila K West
Journal:  Int J Epidemiol       Date:  2014-03-21       Impact factor: 7.196

Review 4.  Resistance surveillance studies: a multifaceted problem--the fluoroquinolone example.

Authors:  A Dalhoff
Journal:  Infection       Date:  2012-03-30       Impact factor: 3.553

5.  Characterization of small ColE-like plasmids mediating widespread dissemination of the qnrB19 gene in commensal enterobacteria.

Authors:  Lucia Pallecchi; Eleonora Riccobono; Samanta Sennati; Antonia Mantella; Filippo Bartalesi; Christian Trigoso; Eduardo Gotuzzo; Alessandro Bartoloni; Gian Maria Rossolini
Journal:  Antimicrob Agents Chemother       Date:  2009-12-14       Impact factor: 5.191

6.  Molecular mechanisms of antibiotic resistance in diarrhoeagenic Escherichia coli isolated from children.

Authors:  Susan Mosquito; Joaquim Ruiz; María J Pons; David Durand; Francesca Barletta; Theresa J Ochoa
Journal:  Int J Antimicrob Agents       Date:  2012-10-15       Impact factor: 5.283

7.  Diarrheagenic Escherichia coli phylogroups are associated with antibiotic resistance and duration of diarrheal episode.

Authors:  Susan Mosquito; Maria J Pons; Maribel Riveros; Joaquim Ruiz; Theresa J Ochoa
Journal:  ScientificWorldJournal       Date:  2015-02-25

8.  Global fluoroquinolone resistance epidemiology and implictions for clinical use.

Authors:  Axel Dalhoff
Journal:  Interdiscip Perspect Infect Dis       Date:  2012-10-14

9.  Quinolone resistance in absence of selective pressure: the experience of a very remote community in the Amazon forest.

Authors:  Lucia Pallecchi; Alessandro Bartoloni; Eleonora Riccobono; Connie Fernandez; Antonia Mantella; Donata Magnelli; Dario Mannini; Marianne Strohmeyer; Filippo Bartalesi; Hugo Rodriguez; Eduardo Gotuzzo; Gian Maria Rossolini
Journal:  PLoS Negl Trop Dis       Date:  2012-08-28

10.  Biannual Treatment of Preschool Children with Single Dose Azithromycin to Reduce Mortality: Impact on Azithromycin Resistance in the MORDOR Trial in Tanzania.

Authors:  Evan M Bloch; Christian L Coles; Mabula Kasubi; Jerusha Weaver; Zakayo Mrango; Beatriz Munoz; Thomas M Lietman; Sheila K West
Journal:  Am J Trop Med Hyg       Date:  2020-09       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.